New hope for advanced cancers? early trial of CS23546 begins
NCT ID NCT06245122
First seen Apr 22, 2026 · Last updated May 07, 2026 · Updated 2 times
Summary
This study is testing a new drug called CS23546 in people with advanced solid tumors or lymphoma that have not responded to or cannot tolerate standard treatments. The main goals are to find a safe dose and understand how the drug works in the body. About 156 participants will take part in this early-phase trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Cancer
RECRUITINGGuangzhou, China
Contact
Contact
Conditions
Explore the condition pages connected to this study.